VANCOUVER, Feb. 2 /CNW/ - Welichem Biotech is pleased to announce the
successful completion of two Phase II clinical trials with WBI-1001 on
psoriasis and atopic dermatitis. Both studies were 12-week,
double-blinded, placebo-controlled clinical trials conducted under the
regulatory guidelines of Health Canada. Based on analysis of the data,
both the primary and secondary efficacy and safety endpoints were met
in both studies.
ON BEHALF OF THE BOARD
Dr. John M. Webster, Chairman of the Board
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune disease and
SOURCE Welichem Biotech Inc.
For further information:
Liren Tang, PhD.
Chief Executive Officer.
Tel.: (604) 432-1703, E-mail: email@example.com